top of page
The Professional Network for Healthcare Experts
Pfizer signs Enodia Therapeutics research and licensing agreement worth more than $500 million for Sec61 protein degradation
Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition.
nuaxia
Oct 142 min read
Lilly expands Gate Bioscience collaboration for molecular-gate protein degraders
Eli Lilly and Gate Bioscience have expanded their drug-discovery collaboration by adding a new target and an option for a second under Gate's Molecular Gate platform.
nuaxia
Oct 72 min read
Atavistik Bio and Roche sign allosteric drug discovery collaboration worth up to $1.9bn
The collaboration gives Roche access to Atavistik Bio's AMPS platform to discover allosteric small molecules across cardiovascular, renal and metabolic disease targets.
nuaxia
Sep 281 min read
Lilly and InnoCare sign drug-discovery collaboration worth up to $3.35bn
Lilly and InnoCare have entered a multi-target research and licensing collaboration potentially worth $3.35 billion to discover and develop new medicines.
nuaxia
Sep 252 min read
AbbVie and Iambic enter AI-driven drug discovery collaboration across immunology, neuroscience and oncology
AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.
nuaxia
Sep 222 min read
bottom of page